Your browser doesn't support javascript.
loading
Associations of Epstein-Barr Virus-Positive Gastric Adenocarcinoma with Circulating Mediators of Inflammation and Immune Response.
Camargo, M Constanza; Sivins, Armands; Isajevs, Sergejs; Folkmanis, Valdis; Rudzite, Dace; Gulley, Margaret L; Offerhaus, G Johan; Leja, Marcis; Rabkin, Charles S.
Afiliación
  • Camargo MC; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr., BG 9609/6E338, Bethesda, MD 20892, USA. camargomc@mail.nih.gov.
  • Sivins A; Institute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. armands1@hotmail.com.
  • Isajevs S; Institute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. sergisajevs@inbox.lv.
  • Folkmanis V; Institute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. valdis.folkmanis@lu.lv.
  • Rudzite D; Institute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. dacerudzite2008@inbox.lv.
  • Gulley ML; Department of Pathology, University of North Carolina, Chapel Hill, NC 27599, USA. margaret_gulley@med.unc.edu.
  • Offerhaus GJ; Department of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands. g.j.a.offerhaus@umcutrecht.nl.
  • Leja M; Institute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, LV1586 Riga, Latvia. cei@latnet.lv.
  • Rabkin CS; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr., BG 9609/6E338, Bethesda, MD 20892, USA. rabkinc@exchange.nih.gov.
Cancers (Basel) ; 10(9)2018 Aug 23.
Article en En | MEDLINE | ID: mdl-30142953
Epstein-Barr virus (EBV)-positive gastric adenocarcinoma exhibits locally intense inflammation but systemic manifestations are uncertain. Our study examined whether circulating mediators of inflammation and immune response differ by tumor EBV status. From a Latvian series of 302 gastric cancer cases, we measured plasma levels of 92 immune-related proteins in the 28 patients with EBV-positive tumors and 34 patients with EBV-negative tumors. Eight markers were statistically significantly higher with tumor EBV positivity: chemokine C-C motif ligand (CCL) 20 (Odds Ratio (OR) = 3.6; p-trend = 0.001), chemokine C-X-C motif ligand 9 (OR = 3.6; p-trend = 0.003), programmed death-ligand 1 (PD-L1; OR = 3.4; p-trend = 0.004), interleukin (IL)-10 (OR = 2.4; p-trend = 0.019), CCL19 (OR = 2.3; p-trend = 0.019), CCL11 (OR = 2.2; p-trend = 0.026), IL-17A (OR = 2.0; p-trend = 0.038) and CCL8 (OR = 1.9; p-trend = 0.049). Systemic responses to EBV-positive gastric cancer are characterized by alterations in chemokines and PD-L1. Profiling of these molecules may enable non-invasive diagnosis of EBV status when tumor tissue is unavailable. Our findings provide theoretical justification for clinical evaluations of immune checkpoint therapy for EBV-positive gastric cancer.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza